

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-003:
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/613,355	
			Filing Date	07/11/2000	
			First Named Inventor	LIPPS	
			Group Art Unit	1646	
			Examiner Name		
Sheet	1	of	2	Attorney Docket Number	FWL PAT 013US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7?
		LEVI-MONTALCINI et al-- "In vitro experiments on the effects of mouse sarcomas..." Cancer Res 14:49-57 (1954)	
		COHEN, S.-- "Purification and metabolic effects of nerve growth...protein from snake..." J Biol Chem 234:1124-37 (1959)	
		COHEN, S.-- "Purification of nerve growth...protein from mouse salivary glands..." Proc Natl Acad Sci 46:302-11 (1960)	
		GOLDSTEIN, LD et al-- "Isolation of human nerve growth factor..." Neurochem. Research 3:175-83 (1978)	
		JOHNSON D.G. et al-- "A sensitive radioimmunoassay for 76 nerve growth factor antigens..." J Neurochem 18:2355-62 (1971)	
		FURUKAWA, S. et al-- "A... immunoassay for mouse... nerve growth factor" J Neurochem. 40:734-44 (1983)	
		LEVI-MONTALCINI, R-- "The nerve growth factor 35 years later" Science 237:1154-62 (1987)	
		THORPE, L. et al-- "Receptors for NGF on rat spleen mononuclear cells" J Neurosci Res 17:128-134 (1987)	
		ALOE, L. et al-- "Mast cells increase in... rats injected with the nerve growth factor" Brain Rs 133:358-66 (1977)	
		BISCHOFF, S. et al-- "Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils" Blood 79:2662-69 (1992)	
		WILCOX, C. et al-- "Nerve growth factor deprivation results in the reactivation of latent herpes simplex virus in vitro." J Virol. 61:2311-15 (1987)	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

(Information Disclosure Statement by Applicant (PTO/SB/08B) Other Prior Art—NonPatent Literature Documents (1449A/PTO) [6-2.1]—page 1 of 1)


Please type a plus sign (+) inside this box → 

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/613,355
		Filing Date	07/11/2000
		First Named Inventor	LIPPS
		Group Art Unit	1646
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	FWL PAT 013 US	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PERX, E-- "Nerve growth factor... a link in etiology..." Alzheimer Disease and Associated Disorders 4:1-13 (1990)	
		APPEL, S-- "A unifying hypothesis for the cause of amyotrophic lateral sclerosis..." Ann. Neurol. 10:449-505 (1981)	
		HEFTI, F-- "Alzheimer's disease caused by lack of nerve growth factor" Ann. Neurol. 20:275-81 (1983)	
		LOREZ, H et al-- "Nerve growth factor increases... after hypoxic injury" Neurosci Lett. 98:339-344 (1989)	
		GOMEZ-DINILLA, F et al-- "NGF receptor immunoreactivity in aged rat brain" Brain Res 479:255-62 (1989)	
		PHELPS, C et al-- "Potential use of nerve growth factor to treat Alzheimers..." Neurobiol Aging 10:205-07 (1989)	
ST		LIPPS, B-- "Biological and immunological properties of nerve growth factor from snake..." J Natural Toxins 7:121-30 (1998)	✓
		WELLS, J-- "Hormone mimicry" Science 273:449-50 (1996)	
		LONGO, F et al-- "Synthetic NGF Peptide Derivatives prevent neuronal death..." J Neuroscience 48:1-27 (1997)	
ST		INOUE, S et al... "Amino acid sequences of nerve growth factors derived from cobra venoms" FEBS letters 279, number 1, 38-40 (1991)	✓
ST		SERVERA, A et al, -- "Comparison of the nerve growth factor proteins from cobra venom and mouse submaxillary gland" Biochemistry 15, no. 1, 35-39 (1976)	✓

Examiner Signature 	Date Considered 12-23-02
--	--------------------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.